Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

ONL Therapeutics

Request full access

Biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors

Ann Arbor, United StatesFounded 2011Biotech & Life Sciences

About ONL Therapeutics

ONL Therapeutics, established in 2011, is a clinical-stage biopharmaceutical company spun out from the University of Michigan. The company's formation was inspired by the clinical work of its co-founder, Dr. David Zacks, a retina specialist at the University of Michigan's Kellogg Eye Center. Dr. Zacks' research into the molecular mechanisms of photoreceptor cell death led to the discovery of the Fas receptor's critical role in the process and the potential for a therapeutic that could block this pathway to preserve vision. This foundational science, focused on a desire to provide more tools for patients facing vision loss, propelled the company's creation with the help of the university's technology transfer office.

The company's business is centered on developing a portfolio of first-in-class therapies to protect retinal cells from Fas-mediated death, a common pathway in numerous retinal diseases. This positions ONL Therapeutics to address significant unmet medical needs across a spectrum of acute and chronic ophthalmic conditions. The business model involves advancing its lead therapeutic candidate, ONL1204, through rigorous clinical trials to gain regulatory approval and eventual commercialization. Revenue generation will be contingent on the successful development, approval, and marketing of its drug candidates, or through strategic partnerships with larger pharmaceutical companies. ONL has successfully raised substantial capital through multiple funding rounds, including a $46.9 million Series B in 2020 and a $65 million Series D in 2024, attracting investment from notable entities like Johnson & Johnson Innovation – JJDC, Novartis Venture Fund, and Bios Partners.

ONL's core product is ONL1204, a small peptide Fas inhibitor administered via intravitreal injection. Its primary function is to block the Fas receptor on retinal cells, which prevents the activation of both cell death (apoptosis) and inflammatory signaling pathways. This neuroprotective mechanism is designed to preserve retinal cell structure and function. A key benefit is its mutation-independent approach, potentially offering a therapeutic solution for various retinal diseases regardless of their genetic origin. The company's clinical development program is robust, with ONL1204 being evaluated for several indications. It has been granted Orphan Drug Designation by the FDA for the treatment of retinal detachment, an acute condition. Furthermore, ONL is actively conducting clinical trials for chronic conditions, including a Phase 2 study for geographic atrophy (GA) associated with age-related macular degeneration (AMD) and a Phase 1b trial for progressing open-angle glaucoma. Early clinical data has been encouraging, showing that ONL1204 can reduce the growth rate of GA lesions and has demonstrated potential for neuroenhancement in glaucoma patients.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2011
Headquarters
Ann Arbor, United States
Employees
37
Open positions
None listed
Dealroom signal
33.1/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
B2B
Investment activity
1 company, latest Dec 2020
Capital deployed
$47M
Preferred round
SERIES B

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES DOther financing Sep 2024 $65M $260M Visionary Ventures · Novartis Venture Fund · Bios Partners · Johnson & Johnson Innovation ↗
SERIES COther financing Mar 2023 $15M $235M Bios Partners · Capital Community Angel Investors · Western Michigan University · PSQ Capital ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

ONL Therapeutics website traffic

Latest recorded traffic for ONL Therapeutics is 3.6K monthly website visits, up 71.4% over the last three months. ONL Therapeutics's team declined 2.6% over the past year.

Latest monthly visits3.6K 3-month web change+71.4% 1-year team growth-2.6%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

ONL Therapeutics in the Ann Arbor ecosystem

Live from Dealroom

The ONL Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

21 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • Capital Community Angel Investors
  • National Institutes of Health
  • National Eye Institute

Series A12 investors entered at this stage

  • InvestMichigan
  • Novartis
  • Western Michigan University
  • Invest Michigan
  • Bios Partners
  • Kaitai Capital
  • Michigan Capital Network
  • ONL Therapeutics
  • Johnson & Johnson Innovation
  • InFocus Capital Partners
  • PSQ Capital
  • Biosciences Research and Commercialization Center

Series B and later5 investors entered at this stage

  • ExSight Ventures
  • Alpine Visionary Venture
  • Visionary Ventures
  • Mayewell Capital
  • Novartis Venture Fund

Other known investors1 additional known investor

  • University of Michigan
Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States94.1%
🇬🇭 Ghana5.9%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about ONL Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See ONL Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.